Navigation Links
Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee

- Pain Reductions Observed at Eight Weeks Sustained up to 12 Weeks and Drug Remains Very Well Tolerated -

SOUTH SAN FRANCISCO, Calif., July 02, 2007 /PRNewswire-FirstCall/ -- Anesiva, Inc. today announced preliminary longer-term, follow-up results from a Phase 2 study showing that a 1mg treatment with Adlea(TM) (formerly 4975) in patients with moderate-to-severe osteoarthritis of the knee produced substantial reductions in pain that persisted for up to 12 weeks.

"The positive preliminary results from this knee pain study further strengthen our belief that Adlea will prove to be a safe and effective drug in multiple osteoarthritis indications," said John P. McLaughlin, chief executive officer of Anesiva. "We are on-track to advance Adlea into late-stage trials in various indications this summer, including a Phase 2/3 trial for osteoarthritis of the knee."

Fifty-five patients with osteoarthritis of the knee were randomized to receive either: (I) a single injection of 1 mg of Adlea (n=36) or (II) three stepped ascending weekly doses totaling 1 mg of Adlea (n=19). At baseline prior to treatment, approximately three quarters of the patients had moderate pain while the other quarter had severe or extreme pain. As was previously reported, patients treated with Adlea demonstrated a 61 percent reduction in mean pain intensity from baseline to week one, and the analgesic effect was sustained at all subsequent weeks to the last scheduled in-clinic assessment at week eight, at which time a 64 percent reduction in pain from baseline was reported. At week 12, pain reductions were sustained. A cohort of 50 patients showed a 65 percent reduction from baseline pain scores. Forty two percent of the patients reported "no pain," 44 percent had "mild pain," and only 14 percent reported "moderate" or "severe" pain. The lengthy duration of clinical benefit is consistent with the known mechanism of action that suggests treatment with Adlea administered as a single injectio
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/1/2008)...EGO, Dec. 1 TargeGen has announced...s from a multi-center, US-based clinical,trial of...as been scheduled at,the 2008 American Society of...he presentation are as follows:, Title: ...oavailable, JAK2-Selective...
(Date:12/1/2008)...APOLIS, Dec. 1 Roche announced tod... differences in perceived pain and,discomfort ass...K blood,glucose monitoring systems and lancing de...indicated that, overall, the ACCU-CHEK Aviva and A...stems and the ACCU-CHEK Multiclix, ACCU-CHEK,Soft...
(Date:12/1/2008)...de study shows the Prox1 gene is a two-way switch ...cells to be reprogrammed so that they lose their i...ls , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-U...esearch Hospital have discovered that a certain di...dentity that it requires the constant expression o...
(Date:12/1/2008)...TH MEETING, Pa., Dec. 1 ...nced that dosing of subjects has begun in study MS...se Phase 1b study of trodusquemine (MSI-1436) in o...a novel therapeutic for the treatment of type 2 di...herally to regulate insulin and leptin pathways th...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Embryos Discarded During IVF Create Stem Cell Lines 10220 1Embryos Discarded During IVF Create Stem Cell Lines 10220 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 1Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 3The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 1The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 2NutraCea Provides Update on Domestic Operations 10215 1NutraCea Provides Update on Domestic Operations 10215 2NutraCea Provides Update on Domestic Operations 10215 3
...atient Lung Cancer Diversity Study, CHICAGO, June ...,lung cancer is the leading cause of cancer death ...ed to be diagnosed,and 16,700 deaths expected this...leading cause of cancer death in Hispanic men and ...ic women.(ii),Researchers at Eli Lilly and Company...
...l CBR of 52% which compares favorably with,the act..., 2007 /PRNewswire-FirstCall/ - AEterna,Zentaris I...n,endocrine therapy and oncology, today announced ...ed a poster outlining Phase 1 and,Phase 2 results ...ction inhibitor compound, for the treatment of pat...
Other Medicine Technology:Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 2Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 3Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 4Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 5Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 7Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 8Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 9Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 10Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 11AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4
(Date:12/2/2008)...o Celebrate With Traditional Holiday Cuisine , ... Food Ministries ( www.angelfoodministries.com ), ...y food at low-costs, to anyone who wishes to parti...include a specialty Christmas Box which includes e...tion. Host sites are now taking orders throughout ...
(Date:12/2/2008)...l Deficiencies in Care for Individuals across the ... Members who recently sought expert medical consul...certainty about their initial diagnosis or course ... , The findings are based on clinical review...s a unique health benefit that calls upon top medi...
(Date:12/2/2008)...ion Highlights Need to Reduce Disparities in Menin... , , BETHESDA, Md., Dec. 2 ... (NFID) S.T.O.P. (Share. Teach. Outreach. Protec...he nation,s leading medical and advocacy organizat...adolescent meningococcal vaccination rates and to ...
(Date:12/2/2008)...it could aid shift workers, people affected by jet...) -- The experimental drug tasimelteon helps treat...fts, according to the results of two new clinical ... randomly assigned to receive either 10 milligrams...ebo. They were monitored for seven nights -- three...
Breaking Medicine News(10 mins):Health News:Angel Food Ministries to Distribute Holiday Grocery Relief 2Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 2Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 2Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 4Health News:Drug Effective for Temporary Sleep Disruptions 2
...unfortunate instances we see couples who are HIV s...If the husband is HIV –1 positive and the wife is ... problem arises because sexual intercourse carries... female partner and through her to the fetus. Sper...
...e unlucky to be afflicted by the deadly chronic my... there's some good news. One of the deadliest fo... kills thousands across the globe. Chronic myel...und and still continues to be one. But there's go...
... medical practice of Acupuncture along with common...and disabling side effects of chemotherapy for bre...stitute of Health (NIH) are to be believed. Acco...search associate at NIH, electro-acupuncture was m...
... blood test can give clue if the heart attack pati...ogged vessels and restore blood flow to their hear...tt analyzed medical records of more than 12,000 he...tients whose white blood cell count is in what is ...
Other Medicine News:Health News:Sperm washing helps couples – Breakthrough in focu 2
Precision near-field imaging combined with the best handling IVUS catheter.
The Medison SonoAce 9900 is a fully digital, NT2000 based ultrasound system, with an integrated workstation that is DICOM compatible, designed for multi-specialty applications including general imagi
Full Digital Color Ultrasound
...armonic Echo technology constructs images using se...rtifacts and noise than fundamental-frequency comp...ogy to transmit distortion-free, fundamental-frequ...equency ultrasound beam is a pure sinusoidal wave,...
Medicine Products: